Tessa Romero
Stock Analyst at JP Morgan
(3.84)
# 594
Out of 4,944 analysts
65
Total ratings
47.92%
Success rate
11.43%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tessa Romero
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Overweight | $30 → $34 | $25.13 | +35.30% | 9 | Jul 24, 2025 | |
| DYN Dyne Therapeutics | Maintains: Neutral | $10 → $9 | $12.24 | -26.47% | 6 | Jul 15, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $68 → $55 | $14.39 | +282.21% | 7 | Jun 18, 2025 | |
| CYTK Cytokinetics | Maintains: Overweight | $71 → $53 | $36.88 | +43.71% | 5 | Jun 9, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Overweight | $16 → $10 | $4.72 | +111.86% | 2 | May 30, 2025 | |
| UPB Upstream Bio | Initiates: Overweight | $38 | $18.55 | +104.85% | 1 | Nov 5, 2024 | |
| NMRA Neumora Therapeutics | Downgrades: Neutral | $18 → $15 | $1.56 | +864.63% | 4 | Nov 5, 2024 | |
| MCRB Seres Therapeutics | Downgrades: Underweight | n/a | $15.97 | - | 2 | Oct 24, 2024 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $18 → $31 | $31.98 | -3.06% | 5 | Oct 14, 2024 | |
| EYPT EyePoint Pharmaceuticals | Maintains: Overweight | $32 → $29 | $11.01 | +163.40% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $31 | $13.73 | +125.78% | 8 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $46 | $36.61 | +25.65% | 6 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $7 | $8.51 | -17.74% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $55 | $37.67 | +46.00% | 2 | Apr 25, 2023 |
ACADIA Pharmaceuticals
Jul 24, 2025
Maintains: Overweight
Price Target: $30 → $34
Current: $25.13
Upside: +35.30%
Dyne Therapeutics
Jul 15, 2025
Maintains: Neutral
Price Target: $10 → $9
Current: $12.24
Upside: -26.47%
Biohaven
Jun 18, 2025
Maintains: Overweight
Price Target: $68 → $55
Current: $14.39
Upside: +282.21%
Cytokinetics
Jun 9, 2025
Maintains: Overweight
Price Target: $71 → $53
Current: $36.88
Upside: +43.71%
Lexeo Therapeutics
May 30, 2025
Maintains: Overweight
Price Target: $16 → $10
Current: $4.72
Upside: +111.86%
Upstream Bio
Nov 5, 2024
Initiates: Overweight
Price Target: $38
Current: $18.55
Upside: +104.85%
Neumora Therapeutics
Nov 5, 2024
Downgrades: Neutral
Price Target: $18 → $15
Current: $1.56
Upside: +864.63%
Seres Therapeutics
Oct 24, 2024
Downgrades: Underweight
Price Target: n/a
Current: $15.97
Upside: -
Scholar Rock Holding
Oct 14, 2024
Maintains: Overweight
Price Target: $18 → $31
Current: $31.98
Upside: -3.06%
EyePoint Pharmaceuticals
Aug 13, 2024
Maintains: Overweight
Price Target: $32 → $29
Current: $11.01
Upside: +163.40%
Aug 12, 2024
Maintains: Overweight
Price Target: $30 → $31
Current: $13.73
Upside: +125.78%
Jun 13, 2024
Reinstates: Neutral
Price Target: $46
Current: $36.61
Upside: +25.65%
Aug 22, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $8.51
Upside: -17.74%
Apr 25, 2023
Maintains: Overweight
Price Target: $54 → $55
Current: $37.67
Upside: +46.00%